Scarica l'app Stockscreener
89.45
1.00%
0.47
Palvella Therapeutics Inc Borsa (PVLA) Ultime notizie
Chardan Boosts Price Target on Palvella Therapeutics to $174 From $110, Keeps Buy Rating - marketscreener.com
FDA grants fast track designation for Palvella’s skin disease therapy By Investing.com - Investing.com Canada
Palvella (Nasdaq: PVLA) secures FDA Fast Track Designation for QTORIN angiokeratomas - Stock Titan
Palvella Therapeutics stock price target raised to $192 at BTIG on positive trial data - Investing.com Canada
Palvella Therapeutics stock price target raised to $143 on positive trial data - Investing.com Canada
Truist Securities raises Palvella Therapeutics stock price target to $190 - Investing.com
Palvella Therapeutics stock maintains Buy rating at Clear Street on pipeline progress - Investing.com UK
Palvella Therapeutics stock price target raised to $200 from $190 at H.C. Wainwright - Investing.com Canada
Palvella Therapeutics stock price target raised to $212 from $122 at Lucid Capital - Investing.com Canada
Palvella stock price target raised to $200 from $120 at Oppenheimer - Investing.com Canada
Palvella Therapeutics (NASDAQ:PVLA) Sets New 52-Week HighHere's What Happened - MarketBeat
'Not for everybody but it's a classic biotech setup': Baral on Palvella Therapeutics - BNN Bloomberg
Palvella Therapeutics stock hits 52-week high at 110.34 USD - Investing.com
Palvella Therapeutics stock maintains Strong Buy rating at Raymond James By Investing.com - Investing.com UK
Palvella Therapeutics stock hits 52-week high at 110.34 USD By Investing.com - Investing.com UK
Palvella Therapeutics Reports Positive Topline Phase 2 Data for Qtorin Gel in Rare Skin Condition - marketscreener.com
Palvella Therapeutics Reports Positive Phase 2 Study Results - TipRanks
Palvella Therapeutics announces positive topline results from phase 2 Toiva clinical trial of Qtorin - marketscreener.com
Palvella Therapeutics Announces Positive Phase 2 TOIVA Study Results - TradingView — Track All Markets
Palvella Therapeutics Announces Positive Topline Results - GlobeNewswire
Frazier Life Sciences Management L.P. Has $16.28 Million Stock Position in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Is Longfor Group Holdings Limited RLF a good long term investmentFederal Reserve Announcements & Small Investment Big Gains - earlytimes.in
Palvella Therapeutics stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Canada
Palvella Therapeutics (PVLA) price target increased by 15.61% to 133.70 - MSN
XTX Topco Ltd Acquires Shares of 17,701 Palvella Therapeutics, Inc. $PVLA - MarketBeat
Palvella Therapeutics Secures New U.S. Patent for QTORIN Rapamycin - MSN
Palvella Therapeutics initiated with a buy at Craig-Hallum - MSN
Palvella Therapeutics (NASDAQ:PVLA) Trading 8% HigherStill a Buy? - MarketBeat
Palvella Therapeutics to Announce Q1 2025 Financial Results and Host Investor Call - MSN
Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Analysts at Craig Hallum - MarketBeat
Palvella Therapeutics (PVLA) Price Target Increased by 15.61% to 133.70 - Nasdaq
Clear Street Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - Nasdaq
BTIG Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - Nasdaq
Clear Street Initiates Coverage on PVLA with a 'Buy' Rating | PV - GuruFocus
This Oklo Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday - Benzinga
BTIG Initiates Palvella Therapeutics With Buy Rating, $167 Price Target - marketscreener.com
BTIG initiates coverage on Palvella Therapeutics stock with Buy rating By Investing.com - Investing.com Canada
Craig-Hallum Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - Nasdaq
Clear Street initiates Palvella Therapeutics stock with Buy rating, $200 target - Investing.com Canada
Will Palvella Therapeutics Inc. (PI6) stock beat revenue estimates2025 Price Targets & Long-Term Investment Growth Plans - Newser
How Palvella Therapeutics Inc. (PI6) stock compares with top peersJuly 2025 Reactions & Safe Capital Preservation Plans - Newser
Lymphatic Malformations Market Expected to Experience Major - openPR.com
Can Palvella Therapeutics Inc. stock sustain revenue growth2025 Volatility Report & Risk Managed Investment Signals - Newser
Palvella Therapeutics (NASDAQ:PVLA) Sees Strong Trading VolumeTime to Buy? - MarketBeat
Will Palvella Therapeutics Inc. (PI6) stock keep high P E multiplesMarket Growth Summary & Risk Managed Trade Strategies - Newser
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives $117.33 Consensus PT from Brokerages - Defense World
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Down 7.9%Should You Sell? - MarketBeat
Tech Rally: How risky is Palvella Therapeutics Inc stock now2025 Geopolitical Influence & Technical Entry and Exit Tips - BỘ NỘI VỤ
Palvella Therapeutics (PVLA) Stock Analysis Report | Financials & Insights - Benzinga
Will Palvella Therapeutics Inc. stock benefit from automationJuly 2025 Rallies & High Yield Stock Recommendations - Newser
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Tiny Biotech’s Big Bet On Rare Skin Diseases - Finimize
Will Palvella Therapeutics Inc. stock continue upward momentumJuly 2025 Market Mood & Weekly Consistent Profit Watchlists - BỘ NỘI VỤ
Palvella Therapeutics stock hits 52-week high at 104.99 USD By Investing.com - Investing.com Australia
Palvella Therapeutics stock hits 52-week high at 104.99 USD - Investing.com India
Palvella Therapeutics, Inc. $PVLA Stake Reduced by Adams Street Partners LLC - MarketBeat
Can Palvella Therapeutics Inc. (PI6) stock survive global slowdownMarket Volume Report & Free Real-Time Market Sentiment Alerts - moha.gov.vn
0.42%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):